Cytosorbents (CTSO) Liabilities and Shareholders Equity (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $40.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 20.12% year-over-year to $40.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.5 million (down 10.48% YoY) and the FY2025 annual result came in at $44.2 million, down 6.73% from the prior year.
• Liabilities and Shareholders Equity slipped to $40.6 million in Q1 2026, from $44.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $83.3 million in Q1 2022 to a low of $40.6 million in Q1 2026.
• A 5-year average of $53.8 million and a median of $50.8 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 34.5% — and 2025, when it gained 7.88%.
• Tracing CTSO's Liabilities and Shareholders Equity over 5 years: stood at $63.2 million in 2022, then slipped by 16.25% to $53.0 million in 2023, then dropped by 10.55% to $47.4 million in 2024, then fell by 6.73% to $44.2 million in 2025, then decreased by 8.19% to $40.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $40.6 million (Q1 2026), $44.2 million (Q4 2025), and $45.8 million (Q3 2025), per Business Quant data.